HCS main assets for pharmacology
- Pharma custom assays
- Neurodegenerative diseases
- Oncology
Why have we decided to focus on cell imaging ?
1. Because this technology allows phenotypic screening to discover new compounds and new targets for complex diseases, such as neurodegenerative diseases and cancer.
On 1178 FDA-approved drugs & 3074 experimental drugs, there are only 394 targets. But the network and regulation of these targets are huge.
Furthermore, complex diseases with multi-cellular and multi-target implication need multi-target drugs.

Figure: Distribution of drugs with respect to number of their targets. The FDA-approved drugs target 394 human proteins in total. Most drugs target only a few proteins, but some have many targets; for example, propiomazine (Largon) and promazine (Sparine) have 14 targets each, and olanzapine (Zyprexa, Zydis) and ziprasidone (Geodon) have 11 targets each. (Yildirim et al. (2007) Computational Biology 25(10): 1119-1126)
2. Because cellular imagery is a muti-parametric assay which enables to follow several parameters within the same experiment.
1 Comment
Meet us at the first DYRK conference in Saint Malo, march 28th to April 1st | HCS-pharma · March 16, 2017 at 9:08 am
[…] Pharmacology […]